Management Team

Eric N. Olson, Ph.D., Chief Scientific Advisor

Eric N. OlsonEric N. Olson, Ph.D. is Professor and Chairman of the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas. One of the world’s leading experts in developmental biology of the heart, Dr. Olson currently holds the Robert A. Welch Distinguished Chair in Science, the Annie and Willie Nelson Professorship in Stem Cell Research, and the Pogue Distinguished Chair in Research on Cardiac Birth Defects at UTSWMC. Prior to his appointment in Dallas, Dr. Olson was both a professor of Biochemistry and Molecular Biology as well as Chemistry at the M.D. Anderson Cancer Center in Houston. He holds BA, Ph.D. and honorary doctorate degrees from Wake Forest University in Winston-Salem, NC. Dr. Olson has received numerous domestic and international awards from organizations such as the American Heart Association, the National Institutes of Health, and Columbia and McGill Universities among others. He is a fellow of the American Academy of Arts and Sciences, the U.S. National Academy of Sciences, and the Institute of Medicine of the National Academy of Sciences Dr. Olson seves on numerous Editorial Boards and scientific societies. In 1996, he was founder of Myogen, Inc., a company that was acquired in 2006 by Gilead Sciences.

Olav B. Bergheim, Executive Chairman

Olav B. BergheimOlav B. Bergheim has more than 30 years of experience in creating and managing life science companies. Mr. Bergheim’s vast experience includes almost 20 years in general management at Baxter Healthcare where he was the Corporate Vice President and President of the $700 million Cardiovascular Group (now Edwards Lifesciences). Prior to his leadership of the Cardiovascular Group, Mr. Bergheim was the President of Immunotherapy Worldwide, the President of BioTech Europe, and the President of Baxter Germany. After leaving Baxter, Mr. Bergheim became a General Partner at the venture capital firm Domain Associates, LLC. During his tenure at Domain, Mr. Bergheim participated in forming several companies including Volcano Corporation and Glaukos Corporation. In 2005, he founded and continues to be principal partner of Fjord Ventures, a Southern California – based investment and management group developing emerging lifescience companies.

Frank Ahmann, President and Chief Operating Officer

Frank AhmannWith more than 25 years of experience in the biotech and medical device industries, Mr. Ahmann has held executive management positions ranging from operations management to new product development and sales and marketing. Mr. Ahmann was involved with the foundation and development of start-ups such as Chimeric Therapies, Inc., Nephrogenex, Inc.,  Allvivo, Inc., and CardioPolymers, Inc. The latter was acquired recently by LoneStar Heart. He has also been a strategy consultant to various biotechnology start-up ventures and venture capital firms in the cardiovascular, oncology, and stem cell therapy sectors. Previously, Mr. Ahmann spent 10 years in management positions in Europe and North America at Baxter International’s Biotech Group and Cardiovascular Group (now Edwards LifeSciences). Among many products, he launched the first comprehensive system for the collection, processing, storage, and administration of hematopoietic stem cells.  A German citizen who grew up in Mexico, Mr. Ahmann is a native Spanish, German, and English speaker with strong ties to the European medical market. Mr. Ahmann holds a BBA with Honors from the University of Texas at Austin and an MBA from Columbia University Graduate School of Business in New York City.

Andy G. Hinson, Vice President, Clinical and Regulatory Affairs

Andy G. HinsonMr. Hinson joined CardioPolymers, now a wholly-owned subsidiary of LoneStar Heart, in November 2004. Mr. Hinson has over 20 years bio-pharmaceutical industry experience in regulatory strategy and clinical development in a variety of cardiovascular areas including arrhythmia, heart failure, hypertension and myocardial injury. Mr. Hinson also has extensive experience managing clinical trials for new biologic-based therapies. Prior to CardioPolymers, Mr. Hinson was senior director of clinical development at AnGes Inc, a biotechnology firm developing novel gene-based approaches for the treatment of cardiovascular disease. Earlier, Mr. Hinson was senior manager of medical and scientific affairs at Procter & Gamble Pharmaceutical. Mr. Hinson holds a B.S. in Biochemistry from the University of Cincinnati.